Shenzhen Hepalink Pharma... (PK)【SHEZF】銘柄情報

Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) (SHEZF) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.4696

( - )

買値

0.453

売値

0.533

出来高

0.00 日の範囲 0.00

0.4696 52 週間の範囲 0.4696

時価総額

689.042M

前日終値

0.4696

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

US$ 4,478,559

発行済株式数

1,467,296,204

配当利回り

0.15 (1.51%)

PER

33.82

1 株当たり利益 (EPS)

0.26

歳入

5.42B

純利益

380.47M

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing O... Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Pharmaceutical preparations, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers pharmaceutical preparations products, such as enoxaparin sodium injection; API products, including heparin and enoxaparin sodium APIs. It also provides molecule biologics CDMO services, which include research and development, manufacturing, quality management, and program management services, as well as technical support services. In addition, the company develops apabetalone (RVX-208), a BET bromodomain protein inhibitor in Phase 3 trial to reduce major adverse cardiovascular events, as well as in Phase 2 trial for diabetic nephropathy and fatty disease; oregovomab, a monoclonal antibody in Phase 3 trial for ovarian cancer, as well as in Phase 2 for pancreatic cancer; tosatoxumab (AR-301), a fully human IgG1 monoclonal antibody in Phase 3 trial for ventilator-associated pneumonia; and H1710, a heparanase inhibitor preparation for solid tumors. Further, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. The company was founded in 1998 and is headquartered in Shenzhen, the People’s Republic of China. 詳細を表示

セクター

Consumer Discretionary

業界

Apparel & Luxury

ウェブサイト

www.hepalink.com

本社

Shenzhen, China

設立

1998

Shenzhen Hepalink Pharmaceutical Group Company Ltd (PK) is listed in the Consumer Discretionary sector of the その他OTC with ticker SHEZF. The last closing price for Shenzhen Hepalink Pharma... (PK) was US$0.47. Over the last year, Shenzhen Hepalink Pharma... (PK) shares have traded in a share price range of US$ 0.4696 to US$ 0.4696.

Shenzhen Hepalink Pharma... (PK) currently has 1,467,296,204 shares in issue. The market capitalisation of Shenzhen Hepalink Pharma... (PK) is US$689.04 million. Shenzhen Hepalink Pharma... (PK) has a price to earnings ratio (PE ratio) of 33.82.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0.4696	0.4696	0.4696	0	0	CS
26	0	0	0.4696	0.4696	0.4696	0	0	CS
52	0	0	0.4696	0.4696	0.4696	0	0	CS
156	-0.251	-34.8320843741	0.7206	0.7206	0.4696	13	0.4696	CS
260	-0.8561	-64.5772044957	1.3257	1.5	0.4696	978	1.24481251	CS